CAMKII HYPERACTIVATION IN SKELETAL MUSCLES IS A DRIVER AND POTENTIAL THERAPEUTIC TARGET OF SARCOPENIA

Qinchuan Wang, Michael Bene, William Fountain, Giovanni Rosales-Soto, Erick Hernandez-Ochoa, Tae Hwan Chung, Jeremy Walston · 2024

Read CAMKII HYPERACTIVATION IN SKELETAL MUSCLES IS A DRIVER AND POTENTIAL THERAPEUTIC TARGET OF SARCOPENIA by Qinchuan Wang, Michael Bene, William Fountain, Giovanni Rosales-Soto, Erick Hernandez-Ochoa, Tae Hwan Chung, Jeremy Walston (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11691850.txt.

Description

Qinchuan Wang and co-authors report in 2024 that an overactive enzyme may drive the muscle loss of aging, and that blocking it helps. The enzyme, CaMKII, normally wakes during contraction to boost muscle work. In old mouse muscle it stayed on even at rest, cut loose from activity, which raised the question of cause.

A virus-delivered blocker in the shin muscle of old mice restored much of their lost force by two years of age. The mirror test, forcing the enzyme on in young muscle, slashed force sharply. The team reads chronic activation as a driver of age-related weakness and a drug target worth chasing.

Catalog record

CREATORQinchuan Wang, Michael Bene, William Fountain, Giovanni Rosales-Soto, Erick Hernandez-Ochoa, Tae Hwan Chung, Jeremy Walston
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11691850

Browse the full library · About the Tower of Babel